The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
The agency OK’d an artificial vessel to restore blood flow in patients, even though its own scientists flagged questionable ...
UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback